Banyu President Quits; Merck VP To Serve As Interim Boss (Japan)
This article was originally published in PharmAsia News
Banyu Pharmaceutical Co. President Haruhiko Hirate will step down on Sept. 30. David Anstice, executive vice president of the firm's U.S. parent Merck & Co., will take over as interim chief until Hirate's successor is chosen. Hirate took office in January 2004 and, due partly to a lack of new products, failed to increase earnings. Sales totaled less than 200 billion yen in fiscal 2006, well below the target of more than 300 billion yen Hirate had set when he took over as president. (Click here for more - May Require Paid Subscription
You may also be interested in...
Amgen and Mylan will face US Food and Drug Administration actions dates on two of their biosimilar candidates in December, while ANDA sponsors have date-certain launches for two generic products.
With the European Commission "carefully assessing" the judgment of Europe's highest court that CBD is not a narcotic, HBW Insight speaks to an expert in cannabis law about what is likely to happen next.
The UK has used a special legislative process to temporarily authorize the use of the BNT-162b2 vaccine, with the first 800,000 shots expected to be delivered within days.